Precision BioSciences to Present at Guggenheim Healthcare Talks 2021 Oncology Day
Precision BioSciences (Nasdaq: DTIL), a clinical stage biotechnology company, announced its participation in the Guggenheim Healthcare Talks 2021 Oncology Day on February 11, 2021, at 2:00 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Precision BioSciences (Nasdaq: DTIL), a clinical stage biotechnology company, announced its participation in the Guggenheim Healthcare Talks 2021 Oncology Day on February 11, 2021, at 2:00 PM ET. A live webcast of the presentation will be available on the company’s website in the Investors & Media section. Precision BioSciences is focused on improving life through its proprietary ARCUS genome editing platform, which aims to develop CAR T immunotherapy and gene correction therapies for genetic and infectious diseases.
Details
News Market Reaction – DTIL
The recorded move for DTIL in the trading session of this news was +3.70%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its proprietary ARCUS® genome editing platform, today announced it will participate in the Guggenheim Healthcare Talks 2021 Oncology Day on February 11, 2021 at 2:00 PM ET.
A live webcast of the presentation will be accessible on the Company’s website, www.precisionbiosciences.com, in the Investors & Media section under Events and Presentations. An archived replay of the webcasts will be available for approximately 30 days following the presentation.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
Investor Contact:
Alex Kelly
Interim Chief Financial Officer
Alex.Kelly@precisionbiosciences.com
Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.